美通社

2024-11-12 14:00

World's First Patent Acquired for Animal Supplement "Pinfenon" (S) (R)

- Patent Covers Invention of Treatment Drug and Prophylactic Drug for Lowering Cardiac Disorder Markers in Dogs as Well as Their Manufacturing Methods -

TOKYO, Nov. 12, 2024 /PRNewswire/ -- Scarecrow Incorporated, based in Tokyo's Shibuya Ward, is pleased to announce that it has acquired the world's first (*) patent for Pinfenon (S) (R), an animal supplement made in Japan, associated with a treatment drug and a prophylactic drug for lowering the atrial natriuretic peptide (ANP) as well as their manufacturing methods. The supplements approved as drugs by the Japan Patent Office are subject to technical transfer in such products as food, shampoos, and essences as new means of allowing anyone to protect small dogs from cardiac disorders.

(*) According to the Japan Patent Office's survey of global common awareness (Paragraph 1, Article 29, the Trademark Act)

Photo1: Patent recently acquired for Supplement Pinfenon (S) (R) series launched in 2004
https://cdn.kyodonewsprwire.jp/prwfile/release/M103184/202410238652/_prw_PI1fl_5xfktVk4.jpg

Mitral regurgitation, a cardiac disorder frequently observed in dogs around the world but particularly in Japan:
Many breeds of small dogs are genetically susceptible to the cardiac disorder called mitral regurgitation, and valvular diseases of the heart, which include mitral regurgitation, are the third most common cause of death in elderly dogs (according to Anicom HD, Japan, 2023). One of the indicators of the severity of this disease is atrial natriuretic peptide (ANP). This is a hormone primarily synthesized and stored in the part of the heart called the atrium before being secreted in the blood and can be measured by a blood test. For this reason, ANP is also referred to as a cardiac biomarker. A patent was acquired for Pinfenon (S) (R) after it was demonstrated to reduce the burden on the heart and lower the level of this ANP.

Photo2: Pinfenon (S) (R) tablets sized 5 mm in diameter for ease of oral administration
https://cdn.kyodonewsprwire.jp/prwfile/release/M103184/202410238652/_prw_PI2fl_HluU8c7p.jpg

Overview:
Name of invention: Treatment drug and prophylactic drug for lowering atrial natriuretic peptide (ANP) as well as manufacturing methods
Registration number: P7542838
Date of registration: August 23, 2024
Patent holder: Scarecrow Incorporated
Inventor: Hiroshi Okawa, Hiroshi Koie
Date of application: February 15, 2024

About the Clinical Study
Prior to the patent acquisition for Pinfenon (S) (R), a clinical study was conducted in 27 dogs with mitral regurgitation at 15 hospitals across Japan. Pinfenon (S) (R) was co-administered for 30 days under continued treatment with the medication for a cardiac disorder in use, and a blood test was conducted at study initiation and after 30 days. In addition, general conditions of difficulty with breathing were observed.

The result of the study showed a significant decrease (improvement) in ANP as a cardiac biomarker, as well as significant improvement in difficulty with breathing. The following graph shows the changes in ANP for 4 animals with the most severe condition among the 27 animals studied. The graph shows a clear decrease (improvement) in values 30 days after the administration of Pinfenon (S) (R) was started.

Graph: https://cdn.kyodonewsprwire.jp/prwfile/release/M103184/202410238652/_prw_PI5fl_437J4115.png

Details of the role of the new supplement in providing support for canine cardiac disorder: https://kyodonewsprwire.jp/attach/202410238652-O1-9I6EwxLq.pdf

Product image: https://cdn.kyodonewsprwire.jp/prwfile/release/M103184/202410238652/_prw_PI4fl_cvzYpuXa.jpg

The main ingredient of Pinfenon (S) (R) is a material extracted from the bark of pine trees called French maritime pine, which is cultivated only in the southwestern part of France. It is a safe, water-soluble natural food product and a natural health ingredient with extremely high physiological activity. More than 800 research papers have been published as a result of the accumulation of data by research institutions globally. Pinfenon (S) (R) also contains supporting ingredients, such as fermented sesame extract and yeast extract, to further enhance the effect in the body of animals.

Product overview: https://kyodonewsprwire.jp/attach/202410238652-O2-Yn51NmI6.pdf

About Scarecrow Incorporated:
https://kyodonewsprwire.jp/attach/202410238652-O3-0U95iTzA.pdf

References:
- Malaysian Small Animal Veterinary Association (MSAVA) National Scientific Conference (NSC) 2022 Proceedings
Hiroshi Koie, "The Effect of Pycnogenol (R) Combination Therapy in Dogs with Mitral Regurgitation Symptom"
https://kyodonewsprwire.jp/attach/202410238652-O4-32zJ4euL.pdf

- Naoki Yoshida, Masahiko Noya, Shuichi Koyama, Hiroshi Okawa, Yuji Matsushita, Jeffry Michael Strong, "Effect of Pinfenon-S (containing Pycnogenol) on Mitral Regurgitation in Dogs," Companion Animal Practice (CAP) 2009
https://kyodonewsprwire.jp/attach/202410238652-O5-951d4rzG.pdf

source: Scarecrow Incorporated

樂本健【活力健康 迎新年】維柏健B+C維他命 激抵買低至$99► 了解詳情

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
4
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
5
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
6
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
7
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
8
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
9
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
10
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
11
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
12
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
13
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
14
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
15
高息定存 | 一周高息合集,銀行年尾搶資金,大眾3個月3.6厘
16
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
17
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
18
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
19
回顧展望-A股自強 | 憧憬國策利好,機構對明年股市走勢樂觀
20
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
21
藍圖2.0 | 旅遊發展藍圖2.0提四大策略,推特色項目智慧旅遊並開拓客源
22
電動車 | 寧德時代:擬發行H股香港上市
23
港股 | 蕭猷華:恒指春節前可挑戰21500點
24
港股 | 蕭猷華:恒指春節前目標21500點
25
去旅行 | 攜程:首十一月香港用戶平均出境航班次數增至1.9次
26
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
27
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
28
微盟 | 炒完微信小店,微盟(2013)遭三名主要股東急沽持股套現
29
易經看世界 | 從乙巳年立春八字看香港前景:哪行業當旺?哪行業運滯?(有片)
30
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老